Toll-like receptors (TLRs) are proteins your immune system uses to detect threats. They sit on and inside your cells, scanning for molecular signatures that signal either an invading pathogen or damage to your own tissue. When a TLR recognizes one of these signatures, it triggers an inflammatory response designed to neutralize the threat. Humans have at least 12 different TLRs, each tuned to recognize different types of danger.
How TLRs Work
Your immune system has two broad layers: an innate system you’re born with and an adaptive system that learns over time. TLRs belong to the innate side. They’re classified as pattern recognition receptors, meaning they don’t identify specific germs the way antibodies do. Instead, they recognize broad molecular patterns shared by entire categories of threats.
These patterns fall into two groups. The first consists of molecules found on bacteria, viruses, fungi, and parasites but not on healthy human cells. The second consists of molecules released when your own cells are injured or dying. This means TLRs respond not only to infections but also to internal damage like tissue injury or cell death, making them central players in inflammation of all kinds.
When a TLR locks onto one of these molecular patterns, it kicks off a signaling chain inside the cell. This chain activates proteins called transcription factors, which switch on genes that produce inflammatory molecules. The result is a rapid, broad immune response: inflammation at the site of infection, recruitment of immune cells, and release of chemical signals called cytokines that coordinate a wider defense.
Where TLRs Are Located
Not all TLRs sit in the same place. Some are anchored in the outer membrane of cells, facing outward where they can intercept bacteria and fungi before they enter. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 all work from the cell surface.
Others are stationed inside the cell, on the walls of compartments called endosomes. TLR3, TLR7, TLR8, and TLR9 operate from this interior position, which makes them well suited to detect viruses. When a virus enters a cell and its genetic material gets exposed during processing, these interior TLRs are waiting. Some TLRs, like TLR4, can actually function from both locations, triggering different signaling pathways depending on where the encounter happens.
What Each TLR Detects
Each TLR is tuned to a different type of molecular pattern. TLR4 is one of the best studied. It detects lipopolysaccharide (LPS), a molecule found in the outer membrane of certain bacteria. This is the receptor responsible for much of the immune reaction during bacterial infections, and it was the first mammalian TLR whose function was identified.
TLR2 (often pairing with TLR1 or TLR6) recognizes components from a wide range of bacteria, fungi, and parasites. TLR5 detects flagellin, the protein that makes up bacterial tails used for swimming. TLR3 detects double-stranded RNA, a molecule that accumulates during viral infections. TLR7 and TLR8 recognize single-stranded RNA from viruses, while TLR9 picks up specific DNA sequences common in bacteria and viruses but rare in human DNA. TLR10 is the least understood, but it’s found on certain immune cells and in the gut lining.
Two Signaling Pathways
Once activated, TLRs relay their signal through one of two main routes inside the cell. Most TLRs use an adapter protein called MyD88, which rapidly activates inflammatory gene programs. This pathway is fast and produces a strong burst of inflammation.
The second pathway uses a different adapter called TRIF. TLR3 signals exclusively through TRIF, and TLR4 can use both pathways. The TRIF pathway is especially important for antiviral defense because it triggers the production of interferons, molecules that put neighboring cells into a defensive state against viral invasion. The fact that TLR4 can use both pathways explains why it produces such a powerful immune response: it fires two signaling cascades simultaneously.
Connecting Innate and Adaptive Immunity
TLRs do more than trigger immediate inflammation. They also serve as a bridge to your adaptive immune system, the slower but more precise branch that produces antibodies and long-term memory. This connection runs through dendritic cells, a type of immune cell that patrols your tissues looking for threats.
When TLRs on a dendritic cell detect a pathogen, the cell undergoes a transformation called maturation. It starts displaying pieces of the pathogen on its surface, ramps up molecules that help activate T cells, and produces large amounts of a cytokine called IL-12. It also gains the ability to migrate to lymph nodes, where it presents the pathogen fragments to T cells and essentially tells the adaptive immune system what to attack. In experiments, dendritic cells matured by TLR signals triggered roughly nine times more activity from T cells than unstimulated dendritic cells. Without TLR activation, the adaptive immune system would be far slower and weaker in its response.
When TLRs Go Wrong
Because TLRs trigger inflammation, problems arise when they’re activated inappropriately or excessively. In autoimmune diseases, the immune system attacks the body’s own tissues, and TLR signaling often plays a role in sustaining that attack.
In systemic lupus erythematosus (lupus), fragments of the body’s own DNA and RNA form complexes that activate TLR7 and TLR9, driving the production of antibodies against the body’s own molecules. In rheumatoid arthritis, RNA released from dying cells in inflamed joints activates TLR3 on nearby tissue cells, and fragments of structural proteins in the joint lining activate TLR4, perpetuating inflammation. In multiple sclerosis, TLR2 and TLR4 activation on immune cells promotes the production of inflammatory signals that drive the immune attack on nerve insulation.
Genetic variations in TLR genes also affect disease risk. People carrying certain variants of the TLR4 gene face higher susceptibility to sepsis, severe respiratory infections, and tuberculosis. A specific variant of TLR2 has been linked to increased risk of severe infections in critically ill patients and to complications from cytomegalovirus after liver transplantation.
TLRs in Medicine
Because TLRs are so effective at jumpstarting immune responses, researchers have found ways to harness them. Three TLR-targeting agents have been approved for use in humans. The first is BCG, an attenuated strain of bacteria originally developed as a tuberculosis vaccine but also used to treat early-stage bladder cancer by activating TLR2 and TLR4 on immune cells in the bladder wall.
The second is monophosphoryl lipid A (MPL), a modified version of the bacterial molecule that activates TLR4. MPL is used as a vaccine booster in Cervarix, the HPV vaccine, where it strengthens the immune response against human papillomavirus. The third is imiquimod, a cream applied to the skin that activates TLR7. It’s used to treat precancerous skin patches, superficial skin cancers, and genital warts by triggering a localized immune response that clears abnormal cells.
How TLRs Were Discovered
The story of TLRs began with fruit flies. In 1996, Jules Hoffmann and Bruno Lemaitre discovered that a gene called “Toll,” previously known only for its role in fly embryo development, was essential for the fly’s defense against fungal infections. Flies with a broken Toll gene couldn’t produce antifungal compounds and died from infections that healthy flies easily survived.
Two years later, Bruce Beutler and Alexander Poltorak identified TLR4 as the receptor for bacterial LPS in mammals, solving a decades-old mystery about how the immune system detects one of the most potent bacterial molecules. This discovery transformed the understanding of innate immunity, revealing it to be not a crude, nonspecific defense but a sophisticated detection system with distinct receptors for different threats. Hoffmann and Beutler shared the 2011 Nobel Prize in Physiology or Medicine for this work.